Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced-cycle BG followed by ZG as first-line treatment for follicular lymphoma
ChiCTR2400094168Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Dec 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine, obinutuzumab and zanubrutinib in follicular lymphoma (FL), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Complete response rate. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
bendamustineobinutuzumabzanubrutinib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on ChiCTR2400094168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094168.